AKBA
Price
$3.13
Change
+$0.12 (+3.99%)
Updated
Aug 28 closing price
Capitalization
829.9M
69 days until earnings call
CLRPF
Price
$2.10
Change
-$0.15 (-6.67%)
Updated
Aug 28 closing price
Capitalization
768.22M
Interact to see
Advertisement

AKBA vs CLRPF

Header iconAKBA vs CLRPF Comparison
Open Charts AKBA vs CLRPFBanner chart's image
Akebia Therapeutics
Price$3.13
Change+$0.12 (+3.99%)
Volume$3.1M
Capitalization829.9M
Clarity Pharmaceuticals
Price$2.10
Change-$0.15 (-6.67%)
Volume$5.5K
Capitalization768.22M
AKBA vs CLRPF Comparison Chart in %
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. CLRPF commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a StrongBuy and CLRPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (AKBA: $3.13 vs. CLRPF: $2.10)
Brand notoriety: AKBA and CLRPF are both not notable
AKBA represents the Pharmaceuticals: Generic, while CLRPF is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 86% vs. CLRPF: 116%
Market capitalization -- AKBA: $829.9M vs. CLRPF: $768.22M
AKBA [@Pharmaceuticals: Generic] is valued at $829.9M. CLRPF’s [@Biotechnology] market capitalization is $768.22M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileCLRPF’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • CLRPF’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than CLRPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 4 TA indicator(s) are bullish while CLRPF’s TA Score has 4 bullish TA indicator(s).

  • AKBA’s TA Score: 4 bullish, 5 bearish.
  • CLRPF’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both AKBA and CLRPF are a bad buy in the short-term.

Price Growth

AKBA (@Pharmaceuticals: Generic) experienced а -1.88% price change this week, while CLRPF (@Biotechnology) price change was -10.64% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.61%. For the same industry, the average monthly price growth was +12.19%, and the average quarterly price growth was +85.29%.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Reported Earning Dates

AKBA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.61% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($830M) has a higher market cap than CLRPF($768M). AKBA YTD gains are higher at: 64.737 vs. CLRPF (-22.366). AKBA has higher annual earnings (EBITDA): 11M vs. CLRPF (-66.98M).
AKBACLRPFAKBA / CLRPF
Capitalization830M768M108%
EBITDA11M-66.98M-16%
Gain YTD64.737-22.366-289%
P/E RatioN/AN/A-
Revenue204MN/A-
Total Cash137MN/A-
Total Debt53.4MN/A-
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
61
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBACLRPF
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
72%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
66%
Advances
ODDS (%)
Bullish Trend 8 days ago
86%
Bullish Trend 23 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
Bearish Trend 9 days ago
65%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRSCX30.24N/A
N/A
Nuveen Large Cap Responsible Eq Ret
JHEIX20.08N/A
N/A
JHancock Equity Income A
GTSAX30.31N/A
N/A
Invesco Small Cap Growth A
TBCUX16.94N/A
N/A
Tweedy, Browne Intl Val II - Ccy UnH
VSQAX18.13N/A
N/A
Invesco MSCI World SRI Index A

CLRPF and

Correlation & Price change

A.I.dvisor tells us that CLRPF and SBHMY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRPF and SBHMY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRPF
1D Price
Change %
CLRPF100%
-6.67%
SBHMY - CLRPF
24%
Poorly correlated
N/A
BOLD - CLRPF
23%
Poorly correlated
N/A
AKBA - CLRPF
21%
Poorly correlated
+3.99%
DOSEF - CLRPF
12%
Poorly correlated
N/A
ACUT - CLRPF
9%
Poorly correlated
+4.21%
More